# Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)

> **NCT01210131** · NA · WITHDRAWN · sponsor: **Maastricht Radiation Oncology**

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** [18F]HX4

## Key facts

- **NCT ID:** NCT01210131
- **Lead sponsor:** Maastricht Radiation Oncology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210131, "Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01210131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*